Article Text

Download PDFPDF

Engaging African ancestry participants in SLE clinical trials
  1. Aderike Anjorin1 and
  2. Peter Lipsky2
  1. 1 RILITE Research Institute, and University of Virginia, Charlottesville, Virginia, USA
  2. 2 RILITE Research Institute, Charlottesville, Virginia, USA
  1. Correspondence to Dr Peter Lipsky; peterlipsky{at}


SLE is a complex autoimmune disease with genetic and clinical differences between patients that appear to reside along ancestral lines. Over the last 20 years, a preponderance of evidence has shown that SLE is more common and severe in minority populations, particularly in African ancestry (AA) women. However, in clinical trials for new therapies of SLE, AA is often under-represented. Without enrolling sufficient AA participants, it is difficult to ascertain the safety and efficacy of new potential therapies among individuals with SLE of different ancestries. Although enrolling minority populations in clinical trials has been a significant challenge for many reasons, the various stakeholders involved in clinical research could act within their own realms to develop new paradigms and policies to bolster the inclusion of AA in the development of new therapies.

  • SLE
  • clinical trials
  • disparities

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

View Full Text

Statistics from


  • Contributors AA and PL conceived of the project and wrote the manuscript. AA carried out the structured review.

  • Funding This study was funded by RILITE Foundation.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement All data used in the preparation of this manuscript are in the public domain.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.